{"id":"https://openalex.org/W4386726953","doi":"https://doi.org/10.1093/bjd/ljad253","title":"When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials","display_name":"When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials","publication_year":2023,"publication_date":"2023-09-03","ids":{"openalex":"https://openalex.org/W4386726953","doi":"https://doi.org/10.1093/bjd/ljad253","pmid":"https://pubmed.ncbi.nlm.nih.gov/37708254"},"language":"en","primary_location":{"id":"doi:10.1093/bjd/ljad253","doi":"https://doi.org/10.1093/bjd/ljad253","is_oa":true,"landing_page_url":"https://doi.org/10.1093/bjd/ljad253","pdf_url":"https://academic.oup.com/bjd/advance-article-pdf/doi/10.1093/bjd/ljad253/51555209/ljad253.pdf","source":{"id":"https://openalex.org/S45720283","display_name":"British Journal of Dermatology","issn_l":"0007-0963","issn":["0007-0963","1365-2133"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Dermatology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://academic.oup.com/bjd/advance-article-pdf/doi/10.1093/bjd/ljad253/51555209/ljad253.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5070708949","display_name":"Brett King","orcid":"https://orcid.org/0000-0002-4576-4616","observed_orcids":["https://orcid.org/0000-0002-4576-4616"]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Brett King","raw_affiliation_strings":["Yale School of Medicine , New Haven, CT , USA"],"raw_orcid":"https://orcid.org/0000-0002-4576-4616","affiliations":[{"raw_affiliation_string":"Yale School of Medicine , New Haven, CT , USA","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002475506","display_name":"Jerry Shapiro","orcid":"https://orcid.org/0000-0002-2971-1223","observed_orcids":["https://orcid.org/0000-0002-2971-1223"]},"institutions":[{"id":"https://openalex.org/I4210086933","display_name":"NYU Langone Health","ror":"https://ror.org/005dvqh91","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210086933"]},{"id":"https://openalex.org/I57206974","display_name":"New York University","ror":"https://ror.org/0190ak572","country_code":"US","type":"education","lineage":["https://openalex.org/I57206974"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jerry Shapiro","raw_affiliation_strings":["New York University Langone Health , New York City, NY , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"New York University Langone Health , New York City, NY , USA","institution_ids":["https://openalex.org/I4210086933","https://openalex.org/I57206974"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002193039","display_name":"Manabu Ohyama","orcid":"https://orcid.org/0000-0002-2662-5717","observed_orcids":["https://orcid.org/0000-0002-2662-5717"]},"institutions":[{"id":"https://openalex.org/I190930483","display_name":"Kyorin University","ror":"https://ror.org/0188yz413","country_code":"JP","type":"education","lineage":["https://openalex.org/I190930483"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Manabu Ohyama","raw_affiliation_strings":["Department of Dermatology, Kyorin University Faculty of Medicine , Tokyo , Japan"],"raw_orcid":"https://orcid.org/0000-0002-2662-5717","affiliations":[{"raw_affiliation_string":"Department of Dermatology, Kyorin University Faculty of Medicine , Tokyo , Japan","institution_ids":["https://openalex.org/I190930483"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009079207","display_name":"Alexander Egeberg","orcid":"https://orcid.org/0000-0001-8257-1816","observed_orcids":["https://orcid.org/0000-0001-8257-1816"]},"institutions":[{"id":"https://openalex.org/I124055696","display_name":"University of Copenhagen","ror":"https://ror.org/035b05819","country_code":"DK","type":"education","lineage":["https://openalex.org/I124055696"]},{"id":"https://openalex.org/I2801941904","display_name":"Bispebjerg Hospital","ror":"https://ror.org/00td68a17","country_code":"DK","type":"healthcare","lineage":["https://openalex.org/I2801941904","https://openalex.org/I2802567020"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"Alexander Egeberg","raw_affiliation_strings":["Department of Clinical Medicine, University of Copenhagen , Copenhagen , Denmark","Department of Dermatology, Bispebjerg Hospital , Copenhagen , Denmark"],"raw_orcid":"https://orcid.org/0000-0001-8257-1816","affiliations":[{"raw_affiliation_string":"Department of Clinical Medicine, University of Copenhagen , Copenhagen , Denmark","institution_ids":["https://openalex.org/I124055696"]},{"raw_affiliation_string":"Department of Dermatology, Bispebjerg Hospital , Copenhagen , Denmark","institution_ids":["https://openalex.org/I2801941904"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022246846","display_name":"Bianca Maria Piraccini","orcid":"https://orcid.org/0000-0001-6537-9689","observed_orcids":["https://orcid.org/0000-0001-6537-9689"]},"institutions":[{"id":"https://openalex.org/I4210097083","display_name":"IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola","ror":"https://ror.org/00t4vnv68","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210097083"]},{"id":"https://openalex.org/I9360294","display_name":"University of Bologna","ror":"https://ror.org/01111rn36","country_code":"IT","type":"education","lineage":["https://openalex.org/I9360294"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Bianca Maria Piraccini","raw_affiliation_strings":["Department of Medical and Surgical Sciences University of Bologna , Bologna , Italy","Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna , Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical and Surgical Sciences University of Bologna , Bologna , Italy","institution_ids":["https://openalex.org/I9360294"]},{"raw_affiliation_string":"Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Bologna , Italy","institution_ids":["https://openalex.org/I4210097083"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024984896","display_name":"Brittany G. Craiglow","orcid":"https://orcid.org/0000-0001-8970-7691","observed_orcids":["https://orcid.org/0000-0001-8970-7691"]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brittany Craiglow","raw_affiliation_strings":["Yale School of Medicine , New Haven, CT , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Yale School of Medicine , New Haven, CT , USA","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035044854","display_name":"Rodney Daniel Sinclair","orcid":"https://orcid.org/0000-0001-6751-1428","observed_orcids":["https://orcid.org/0000-0001-6751-1428"]},"institutions":[{"id":"https://openalex.org/I165779595","display_name":"The University of Melbourne","ror":"https://ror.org/01ej9dk98","country_code":"AU","type":"education","lineage":["https://openalex.org/I165779595"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Rodney Sinclair","raw_affiliation_strings":["University of Melbourne , Melbourne , Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Melbourne , Melbourne , Australia","institution_ids":["https://openalex.org/I165779595"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102013389","display_name":"Yun-Fei Chen","orcid":"https://orcid.org/0000-0003-0981-1195","observed_orcids":["https://orcid.org/0000-0003-0981-1195"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yun-Fei Chen","raw_affiliation_strings":["Eli Lilly and Company , Indianapolis, IN , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company , Indianapolis, IN , USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102330719","display_name":"Wen-Shuo Wu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wen-Shuo Wu","raw_affiliation_strings":["Eli Lilly and Company , Indianapolis, IN , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company , Indianapolis, IN , USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047941838","display_name":"Yuxin Ding","orcid":"https://orcid.org/0000-0001-8968-9147","observed_orcids":["https://orcid.org/0000-0001-8968-9147"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yuxin Ding","raw_affiliation_strings":["Eli Lilly and Company , Indianapolis, IN , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company , Indianapolis, IN , USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053940783","display_name":"Najwa Somani","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Najwa Somani","raw_affiliation_strings":["Eli Lilly and Company , Indianapolis, IN , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company , Indianapolis, IN , USA","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5079569711","display_name":"Yves Dutronc","orcid":"https://orcid.org/0000-0002-1284-1152","observed_orcids":["https://orcid.org/0000-0002-1284-1152"]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yves Dutronc","raw_affiliation_strings":["Eli Lilly and Company , Indianapolis, IN , USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company , Indianapolis, IN , USA","institution_ids":["https://openalex.org/I168537998"]}]}],"institutions":[],"countries_distinct_count":5,"institutions_distinct_count":10,"corresponding_author_ids":["https://openalex.org/A5070708949"],"corresponding_institution_ids":["https://openalex.org/I32971472"],"apc_list":{"value":3416,"currency":"GBP","value_usd":4249},"apc_paid":{"value":3416,"currency":"GBP","value_usd":4249},"fwci":15.8793,"has_fulltext":true,"cited_by_count":63,"citation_normalized_percentile":{"value":0.99565331,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":100},"biblio":{"volume":"189","issue":"6","first_page":"666","last_page":"673"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11167","display_name":"Hair Growth and Disorders","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11167","display_name":"Hair Growth and Disorders","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11144","display_name":"melanin and skin pigmentation","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1307","display_name":"Cell Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alopecia-areata","display_name":"alopecia areata","score":0.972000002861023},{"id":"https://openalex.org/keywords/baricitinib","display_name":"baricitinib","score":0.9729999899864197},{"id":"https://openalex.org/keywords/treatment-response-trajectories","display_name":"treatment response trajectories","score":0.6759999990463257},{"id":"https://openalex.org/keywords/salt-score","display_name":"SALT score","score":0.7580000162124634},{"id":"https://openalex.org/keywords/growth-mixture-modeling","display_name":"growth mixture modeling","score":0.7490000128746033},{"id":"https://openalex.org/keywords/dose-comparison","display_name":"dose comparison","score":0.5529999732971191},{"id":"https://openalex.org/keywords/treatment-expectations","display_name":"treatment expectations","score":0.5170000195503235},{"id":"https://openalex.org/keywords/disease-severity","display_name":"disease severity","score":0.4259999990463257},{"id":"https://openalex.org/keywords/nonresponders","display_name":"non-responders","score":0.4339999854564667},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.3009999990463257},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.4429999887943268},{"id":"https://openalex.org/keywords/patient-reported-outcomes","display_name":"patient-reported outcomes","score":0.3869999945163727},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.5540000200271606}],"concepts":[{"id":"https://openalex.org/C2777524370","wikidata":"https://www.wikidata.org/wiki/Q5075435","display_name":"Alopecia areata","level":2,"score":0.9729954600334167},{"id":"https://openalex.org/C2778515351","wikidata":"https://www.wikidata.org/wiki/Q9622","display_name":"Scalp","level":2,"score":0.845807671546936},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8405058979988098},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.7680773735046387},{"id":"https://openalex.org/C2776360568","wikidata":"https://www.wikidata.org/wiki/Q2697787","display_name":"Hair loss","level":2,"score":0.4450831413269043},{"id":"https://openalex.org/C3020618081","wikidata":"https://www.wikidata.org/wiki/Q5937811","display_name":"Hair growth","level":2,"score":0.4364674687385559},{"id":"https://openalex.org/C2778946701","wikidata":"https://www.wikidata.org/wiki/Q2989168","display_name":"Hair disease","level":2,"score":0.4326431453227997},{"id":"https://openalex.org/C2779711729","wikidata":"https://www.wikidata.org/wiki/Q424165","display_name":"Minoxidil","level":2,"score":0.43251579999923706},{"id":"https://openalex.org/C42407357","wikidata":"https://www.wikidata.org/wiki/Q521","display_name":"Physiology","level":1,"score":0.054875344038009644}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000506","descriptor_name":"Alopecia Areata","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001384","descriptor_name":"Azetidines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D006197","descriptor_name":"Hair","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011687","descriptor_name":"Purines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D011720","descriptor_name":"Pyrazoles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D012535","descriptor_name":"Scalp","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017326","descriptor_name":"Clinical Trials, Phase III as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1093/bjd/ljad253","doi":"https://doi.org/10.1093/bjd/ljad253","is_oa":true,"landing_page_url":"https://doi.org/10.1093/bjd/ljad253","pdf_url":"https://academic.oup.com/bjd/advance-article-pdf/doi/10.1093/bjd/ljad253/51555209/ljad253.pdf","source":{"id":"https://openalex.org/S45720283","display_name":"British Journal of Dermatology","issn_l":"0007-0963","issn":["0007-0963","1365-2133"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Dermatology","raw_type":"journal-article"},{"id":"pmid:37708254","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/37708254","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The British journal of dermatology","raw_type":"Journal Article"},{"id":"pmh:oai:pure.atira.dk:openaire/709303c2-af3d-4e93-bb3f-160b50ce33c1","doi":null,"is_oa":true,"landing_page_url":"https://researchprofiles.ku.dk/da/publications/709303c2-af3d-4e93-bb3f-160b50ce33c1","pdf_url":null,"source":{"id":"https://openalex.org/S4306401983","display_name":"Research at the University of Copenhagen (University of Copenhagen)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I124055696","host_organization_name":"University of Copenhagen","host_organization_lineage":["https://openalex.org/I124055696"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"King, B, Shapiro, J, Ohyama, M, Egeberg, A, Piraccini, B M, Craiglow, B, Sinclair, R, Chen, Y F, Wu, W S, Ding, Y, Somani, N & Dutronc, Y 2023, 'When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib : Insights from trajectories analyses of patients enrolled in two phase III trials', British Journal of Dermatology, vol. 189, no. 6, pp. 666-673. https://doi.org/10.1093/bjd/ljad253","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:cris.unibo.it:11585/959053","doi":null,"is_oa":true,"landing_page_url":"https://academic.oup.com/bjd/article/189/6/666/7273977","pdf_url":null,"source":{"id":"https://openalex.org/S4306402579","display_name":"Archivio istituzionale della ricerca (Alma Mater Studiorum Universit\u00e0 di Bologna)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210117483","host_organization_name":"Istituto di Ematologia di Bologna","host_organization_lineage":["https://openalex.org/I4210117483"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1093/bjd/ljad253","doi":"https://doi.org/10.1093/bjd/ljad253","is_oa":true,"landing_page_url":"https://doi.org/10.1093/bjd/ljad253","pdf_url":"https://academic.oup.com/bjd/advance-article-pdf/doi/10.1093/bjd/ljad253/51555209/ljad253.pdf","source":{"id":"https://openalex.org/S45720283","display_name":"British Journal of Dermatology","issn_l":"0007-0963","issn":["0007-0963","1365-2133"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311648","host_organization_name":"Oxford University Press","host_organization_lineage":["https://openalex.org/P4310311648","https://openalex.org/P4310311647"],"host_organization_lineage_names":["Oxford University Press","University of Oxford"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"British Journal of Dermatology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307105","display_name":"Amgen","ror":"https://ror.org/03g03ge92"},{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307379","display_name":"National Psoriasis Foundation","ror":"https://ror.org/005gjjf63"},{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320307773","display_name":"GlaxoSmithKline","ror":"https://ror.org/01xsqw823"},{"id":"https://openalex.org/F4320307781","display_name":"Sanofi","ror":"https://ror.org/027vj4x92"},{"id":"https://openalex.org/F4320309086","display_name":"Celgene","ror":"https://ror.org/0527yg379"},{"id":"https://openalex.org/F4320309432","display_name":"F. Hoffmann-La Roche","ror":"https://ror.org/00by1q217"},{"id":"https://openalex.org/F4320311600","display_name":"Regeneron Pharmaceuticals","ror":"https://ror.org/02f51rf24"},{"id":"https://openalex.org/F4320316473","display_name":"Mylan","ror":"https://ror.org/04nsw4151"},{"id":"https://openalex.org/F4320317544","display_name":"Incyte","ror":"https://ror.org/00cvzzg84"},{"id":"https://openalex.org/F4320319146","display_name":"Horizon Therapeutics","ror":null},{"id":"https://openalex.org/F4320319840","display_name":"Coherus Biosciences","ror":"https://ror.org/00mjj2d85"},{"id":"https://openalex.org/F4320323742","display_name":"Kongelig Hofbuntmager Aage Bangs Fond","ror":"https://ror.org/02rytd882"},{"id":"https://openalex.org/F4320325987","display_name":"Galderma","ror":"https://ror.org/05fswdm20"},{"id":"https://openalex.org/F4320328070","display_name":"Sun Pharma","ror":"https://ror.org/04vnqkx80"},{"id":"https://openalex.org/F4320328528","display_name":"Simon Spies Fonden","ror":"https://ror.org/008bfb651"},{"id":"https://openalex.org/F4320332071","display_name":"LEO Pharma","ror":"https://ror.org/05tzrdd39"},{"id":"https://openalex.org/F4320332195","display_name":"Samsung","ror":"https://ror.org/04w3jy968"},{"id":"https://openalex.org/F4320333587","display_name":"Sanofi Genzyme","ror":null},{"id":"https://openalex.org/F4320337601","display_name":"Janssen Pharmaceuticals","ror":"https://ror.org/03qd7mz70"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4386726953.pdf","grobid_xml":"https://content.openalex.org/works/W4386726953.grobid-xml"},"referenced_works_count":13,"referenced_works":["https://openalex.org/W2049804077","https://openalex.org/W2150500189","https://openalex.org/W2521655245","https://openalex.org/W2548580472","https://openalex.org/W2780717174","https://openalex.org/W2883745911","https://openalex.org/W3002900940","https://openalex.org/W3010311971","https://openalex.org/W3139214381","https://openalex.org/W3171539837","https://openalex.org/W4211012025","https://openalex.org/W4220917957","https://openalex.org/W4322621664"],"related_works":["https://openalex.org/W7154598541","https://openalex.org/W4402110915","https://openalex.org/W4406295736","https://openalex.org/W4324057605","https://openalex.org/W4385683576","https://openalex.org/W4411495698","https://openalex.org/W4388908504","https://openalex.org/W4387015134","https://openalex.org/W4388728344","https://openalex.org/W4386981883"],"abstract_inverted_index":{"BACKGROUND:":[0],"Baricitinib":[1],"is":[2,31],"approved":[3],"for":[4,103,345,374],"the":[5,15,21,35],"treatment":[6,26,38,101,372],"of":[7,17,23,27,78,141,145,229,332],"adults":[8],"with":[9,54,74,247,261,299,326,352],"severe":[10,28,55,75,301,311,353],"alopecia":[11],"areata":[12],"(AA).":[13],"In":[14],"absence":[16],"robust":[18],"data":[19],"on":[20,107,201],"patterns":[22,108],"regrowth":[24,348],"during":[25],"AA,":[29,354],"there":[30],"a":[32,146,268,279],"gap":[33],"in":[34,51,132,161,324,349],"knowledge":[36],"regarding":[37],"expectations.":[39],"OBJECTIVES:":[40],"To":[41],"examine":[42],"whether":[43],"different":[44],"clinical":[45,273],"response":[46,142],"subgroups":[47,120,344,358],"could":[48],"be":[49],"identified":[50,109,205,338],"baricitinib-treated":[52,350],"patients":[53,73,115,175,245,298,325,351],"AA":[56,76,302,312],"and":[57,67,155,164,173,183,189,220,232,235,242,251,255,341,355],"factors":[58],"that":[59,356],"contribute":[60],"to":[61,92,122,178,271,306,319,370],"these":[62,357,366],"subgroups.":[63],"METHODS:":[64],"The":[65,227],"BRAVE-AA1":[66],"BRAVE-AA2":[68],"phase":[69],"III":[70],"trials":[71],"enrolled":[72],"[Severity":[77],"Alopecia":[79],"Tool":[80],"(SALT)":[81],"score":[82,134,148,152,281,304,314],"\u2265":[83,127,156],"50":[84,305],"(\u2265":[85],"50%":[86,157],"scalp":[87,346,375],"hair":[88,333,347,376],"loss)].":[89],"Patients":[90],"randomized":[91,177],"baricitinib":[93,180,248,262],"4":[94,181,249,329],"mg":[95,98,182,185],"or":[96,289],"2":[97,184,263],"retained":[99],"their":[100],"allocation":[102],"52":[104],"weeks.":[105],"Based":[106,200],"through":[110],"growth":[111],"mixture":[112],"modelling":[113],"(GMM),":[114],"were":[116,176,294,321],"categorized":[117],"into":[118],"responder":[119,138,207,343],"according":[121],"when":[123],"they":[124],"first":[125],"achieved":[126,192,278],"30%":[128],"improvement":[129],"from":[130,159,365],"baseline":[131,160,165,300,362],"SALT":[133,147,151,162,280],"(SALT30).":[135],"For":[136],"each":[137],"subgroup,":[139],"trajectories":[140],"(i.e.":[143],"achievement":[144],"\u2264":[149,153,282],"20,":[150],"10":[154],"change":[158],"score)":[163],"disease":[166],"characteristics":[167],"are":[168,359],"reported.":[169],"RESULTS:":[170],"Respectively,":[171],"515":[172],"340":[174],"once-daily":[179],"at":[186,194],"baseline;":[187],"69%":[188],"51%,":[190],"respectively,":[191,238,257],"SALT30":[193],"least":[195],"once":[196],"by":[197,211,284,361],"week":[198,212,217,224,285],"52.":[199],"GMM":[202],"findings,":[203],"we":[204],"three":[206],"subgroups:":[208],"early":[209],"(SALT30":[210,215,222],"12),":[213],"gradual":[214,231,288,340],"after":[216,223],"12-week":[218],"36)":[219,286],"late":[221,233,290,342],"36-week":[225],"52).":[226],"proportions":[228],"early,":[230,339],"responders":[234,266,293,317],"nonresponders":[236],"were,":[237],"33%,":[239],"28%,":[240],"8%":[241],"31%":[243],"among":[244,258,297],"treated":[246,260],"mg,":[250],"20%,":[252],"23%,":[253],"9%":[254],"49%,":[256],"those":[259],"mg.":[264],"Early":[265,292],"had":[267],"shorter":[269],"trajectory":[270],"maximal":[272],"outcomes":[274],"(e.g.":[275],">":[276],"78%":[277],"20":[283],"vs.":[287,309],"responders.":[291],"more":[295,322],"frequent":[296,323],"(SALT":[303,313],"<":[307],"95)":[308],"very":[310],"95-100).":[315],"Overall,":[316],"(early":[318],"late)":[320],"short":[327],"(<":[328],"years)":[330],"episodes":[331],"loss.":[334],"CONCLUSIONS:":[335],"These":[336],"analyses":[337,367],"influenced":[360],"characteristics.":[363],"Findings":[364],"will":[368],"help":[369],"inform":[371],"expectations":[373],"regrowth.":[377]},"counts_by_year":[{"year":2026,"cited_by_count":23},{"year":2025,"cited_by_count":27},{"year":2024,"cited_by_count":12},{"year":2023,"cited_by_count":1}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2023-09-15T00:00:00"}